FDA Determines Regulatory Review Period for Patent Extension of MOVANTIK

Summary

The Food and Drug Administration has published a notice determining the regulatory review period for MOVANTIK, a human drug product, following submissions to the U.S. Patent and Trademark Office for patent extension.